Daiichi Life Insurance Co. Ltd. Makes New Investment in United Therapeutics Corporation $UTHR

Daiichi Life Insurance Co. Ltd. bought a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, HoldingsChannel.com reports. The fund bought 8,277 shares of the biotechnology company’s stock, valued at approximately $4,485,000.

A number of other large investors have also made changes to their positions in the company. Commerce Bank purchased a new position in United Therapeutics during the 2nd quarter worth approximately $784,000. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of United Therapeutics in the second quarter valued at $341,000. Evolve Private Wealth LLC purchased a new stake in shares of United Therapeutics in the second quarter valued at $6,900,000. Emerald Investment Advisers LLC acquired a new stake in shares of United Therapeutics in the second quarter worth $5,025,000. Finally, Korea Investment CORP purchased a new position in shares of United Therapeutics during the second quarter valued at $9,645,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity

In other news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $523.14, for a total transaction of $4,342,062.00. Following the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $23,631,280.08. This represents a 15.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $526.96, for a total value of $5,006,120.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $170,968,483.28. This trade represents a 2.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 442,575 shares of company stock valued at $239,326,330. 8.60% of the stock is currently owned by corporate insiders.

United Therapeutics Price Performance

Shares of UTHR stock opened at $513.12 on Monday. United Therapeutics Corporation has a fifty-two week low of $302.19 and a fifty-two week high of $609.35. The stock’s 50-day moving average is $533.08 and its two-hundred day moving average is $537.80. The firm has a market cap of $22.01 billion, a P/E ratio of 18.36, a PEG ratio of 1.74 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same quarter in the prior year, the company posted $6.41 earnings per share. The firm’s revenue was down 1.9% on a year-over-year basis. As a group, research analysts expect that United Therapeutics Corporation will post 26.33 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on UTHR. Royal Bank Of Canada decreased their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. JPMorgan Chase & Co. upped their target price on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Weiss Ratings raised shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 13th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Bank of America lowered their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $646.00.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.